T A B L E O F C O N T E N

Main results
Five studies met the review entry criteria (5537 adults). Primary outcomes: The odds of an exacerbation requiring oral steroids did not differ significantly between treatments (OR 0.89; 95% CI 0.74 to 1.07, four studies, 4949 adults). The odds of an exacerbation leading hospital admission were also not significantly different (OR 1.29; 95% CI 0.68 to 2.47, four studies, 4879 participants). The odds of serious adverse events did not differ significantly between treatments (OR 1.47; 95% CI 0.75, 2.86, three studies, 4054 participants). Secondary outcomes: Lung function outcomes, symptoms, rescue medication, exacerbations leading ED visit/hospital admission and adverse events did not differ statistically between treatments.
Authors' conclusions
The evidence in this review indicates that differences in the requirement for oral steroids and hospital admission between BUD/F and FP/SAL do not reach statistical significance. However, the confidence intervals do not exclude clinically important differences between treatments in reducing exacerbations or causing adverse events. The width of the confidence intervals for the primary outcomes justify further trials in order to better determine the relative effects of these drug combinations. Although this review sought to assess the effects of these drugs in both adults and children, no trials were identified in the under-12s and research in this area is of a high priority.
P L A I N L A N G U A G E S U M M A R Y
The effects of different combinations of inhaled steroids and long-acting beta-agonists for chronic asthma
Persistent asthma often requires the combination of inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABA). This systematic review examined randomised controlled trials comparing two commonly available combinations administered at fixed dose with a single inhaler, fluticasone/salmeterol (FP/SAL) and budesonide/formoterol (BUD/F). We found that the number of adults who required treatment with oral steroids or admission to hospital was similar between the treatments, but that additional trials would improve the precision of our estimates. No statistical differences were found for pulmonary function, rescue medication use and adverse events. Well-designed studies on these questions on different types of patients are needed to confirm and to better explain these findings. In particular studies which assess the effects of these therapies in children are of a high priority. 
Participants experienc-
B A C K G R O U N D
Asthma is a chronic inflammatory disease of the airways, and antiinflammatory treatment is a cornerstone of asthma therapy. Treatment with inhaled corticosteroids (ICS) improves lung function and reduces asthma symptoms in mild persistent asthmatic patients (Adams 2008). Many patients remain symptomatic despite using optimal doses of ICS. However, patients do benefit by the addition of an inhaled long-acting beta2-agonist (LABA). This approach further improves lung function and quality of life in patients with moderate to severe persistent asthma (Ni Chroinin 2005) .
The principal advantage of combining ICS and LABA in one inhaler is the simultaneous delivery of two effective inhaled therapies. This may lead users to better adhere to dosing regimens, especially given concerns over the use of LABA therapy without a regular background steroid (Walters 2007) . Clinicians and people with asthma are faced with a choice between two treatments as maintenance treatment of asthma: the ICS fluticasone and LABA salmeterol preparation marketed as 'Seretide', 'Advair' or 'Viani', and the ICS budesonide and LABA formoterol preparation marketed as 'Symbicort'.
There is some uncertainty as to which particular combination may be suitable. Previous assessments have considered the addition of any LABA to any ICS when the dose of ICS is increased or when the study drugs are titrated according to symptoms (Greenstone 2005; Gibson 2005) . Although the LABAs commonly used in combination preparations have a similar duration of effect of around 12 hours or more, salmeterol and formoterol also have differing pharmacological properties. The onset of action of formoterol is faster than that of salmeterol (Palmqvist 1997; van Noord 1996) and has as rapid an onset of action as salbutamol in asthma (Cazzola 2002) . Some differences exist also between fluticasone and budesonide despite the shared anti-inflammatory effect (Adams 2007) , and so a systematic exploration of the relative efficacy of these different drug combinations is justified.
O B J E C T I V E S
To compare the combinations of salmeterol/fluticasone and budesonide/formoterol in single inhaler devices in chronic asthma in terms of asthma control, safety and lung function.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised, clinical trials comparing single inhaler devices containing combination fluticasone and salmeterol versus budesonide and formoterol. Only studies with a parallel design were eligible as the minimum washout period of inhaled steroids has not been adequately established.
Types of participants
Adults and children with a diagnosis of chronic asthma. We accepted trialist-defined asthma. Any severity of asthma and patients on any co-intervention were eligible (as long as the co-interventions were not part of the randomised treatment) but studies on acute asthma carried out in emergency departments were excluded.
Types of interventions
The preparations considered by this review were the combination of the inhaled steroid fluticasone and long-acting beta-agonist salmeterol (FP/SAL) against the inhaled steroid budesonide and long-acting beta-agonist formoterol (BUD/F) in one inhaler device. We included studies which assessed the combination of drugs in either metered dose inhalers (MDI) or dry powder inhaler (DPI). We considered fixed dose comparisons between these preparations and we have excluded studies assessing the efficacy and safety of different dosing strategies of budesonide/formoterol ('single inhaler therapy' or 'adjustable maintenance dosing') with fixed dose fluticasone/salmeterol. Studies had a minimum duration of 12 weeks in order to meet the entry criteria of this review. 
Types of outcome measures
Search methods for identification of studies
Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and hand searching of respiratory journals and meeting abstracts. All records in the Specialised Register coded as 'asthma' were searched using the following terms:
("single inhaler" or symbicort or seretide or advair or viani) or ((steroid* or corticosteroid* or ICS or fluticasone or FP or Flixotide or budesonide or BUD or Pulmicort) and ("long acting beta agonist*" or "*beta-agonist*" or LABA* or salmeterol or serevent or formoterol or eformoterol or oxis or foradil)) Reference lists of all primary studies and review articles were reviewed for additional references. Authors of identified randomised trials were asked about knowledge of other published and unpublished studies. Manufacturers of combination single inhaler devices were contacted regarding other published and unpublished studies. We contacted trialists and manufacturers in order to obtain unreported data and to establish whether other unpublished or ongoing studies are available for assessment. We undertook additional hand searching of clinical trial web sites (www.clinicalstudyresults.org; www.clinicaltrials.gov; www.fda.gov) and the clinical trial web sites of manufacturers (www.ctr.gsk.co.uk; www.astrazenecaclinicaltrials.com). Searches are current to May 2009.
Data collection and analysis
Selection of studies
Following electronic literature searches, two review authors independently selected articles on the basis of title and/or abstract for full text scrutiny. The authors agreed a list of articles which were retrieved, and they subsequently assessed each reference to determine whether it met the review eligibility criteria.
Data extraction and management
One author (TJL) extracted information from each study for the following characteristics: Design (description of randomisation, blinding, number of study centres and location, number of study withdrawals). Participants (N, mean age, age range of the study, gender ratio, baseline lung function, % on maintenance ICS or ICS/LABA combination & average daily dose of steroid (BDP equivalent), entry criteria).
Intervention (type and dose of component ICS and LABA, dosing schedule, inhaler device, study duration & run-in) Outcomes (type of outcome analysis, outcomes analysed, numerical data) This information was double-checked by a second author (GF & CJC).
Assessment of risk of bias in included studies
We assessed study quality according to whether studies met the following pre-specified quality criteria (as yes, no or unclear, Handbook 2005):
1. Allocation generation -was sequence generation unpredictable?
2. Allocation concealment -were steps taken to prevent foreknowledge of treatment group assignment?
3. Blinding -were the treatments known to the patients, investigators and those assessing outcomes?
4. Withdrawal -were all participants who entered the study accounted for, and was the analysis likely to be biased by the handling of dropouts? This was considered in relation to the outcomes of oral steroid requirement and hospital admission.
5. Selective reporting -was there evidence of unreported outcome data in the trial report(s)?
6. Other bias -was the study free of other types of bias? Additional information were sought on outcomes that were partially reported from the study sponsors.
Dealing with missing data
We contacted study sponsors for additional data which we required for our primary outcomes of oral steroid-treated exacerbations, and exacerbations leading to hospital admission.
Assessment of heterogeneity
We measured statistical variation between studies by the I square statistic (Higgins 2003) . Where this exceeded 20% we also applied random effects modelling to assess whether assuming a distribution of related true effects (rather than a fixed true effect) altered the pooled effect estimate.
Data synthesis
Data were combined with RevMan 5, using a a fixed effect odds ratio for dichotomous variables, and a fixed effect mean difference (calculated as either a weighted mean difference or a mean difference weighted by generic inverse variance) for continuous data variables. For the primary outcome of exacerbations we calculated NNT(benefit) for the different levels of risk as represented by control group event rates (www.nntonline.net), in order to express the number of patients needed to be treated with intervention to prevent one event from occurring.
We generated a summary of findings table for the primary outcomes in the review (exacerbations requiring oral steroids, exacerbations leading to hospital admission, and serious adverse events). We generated the table with GRADEpro software.
Subgroup analysis and investigation of heterogeneity
We intended to subgroup data from adults, adolescents and children in subgroups. Adult studies were considered as those which recruited participants from 18 upwards. Adult and adolescent studies were considered as those which recruited participants from 12 upwards. We considered participants in studies where the upper age limit was 12 years as children, and in studies where the upper age limit was 18 years as children and adolescents. Despite this categorisation we did not identify any studies performed in children less than 12 years of age. Subgroup analyses was performed based on the severity of asthma as assessed according to international guidelines (GINA: controlled, partly controlled, uncontrolled), and trials on patients using oral steroid treatment were considered separately. We restricted subgroup analysis to our primary outcomes.
Sensitivity analysis
Sensitivity analysis was conducted on the risk of bias, where the predefined quality criteria of randomisation, blinding and withdrawal are met. We also considered the impact of dosing and inhaler devices for both interventions. Funnel plots were inspected to assess the presence of publication bias.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. 
Results of the search
Included studies
Population 5537 adult and adolescent participants were recruited to the studies. The studies required participants to have a history of chronic asthma, treated with maintenance inhaled corticosteroids at moderate to high doses prior to study entry. In the five studies, participants had to be stable for one month before the run-in period. Once in the run-in phase, participants were further required to demonstrate the need for frequent reliever inhaler use. On the basis of these characteristics we adjudged the trial populations to be partly controlled, since the requirement for relief medication was in addition to chronically applied inhaled steroids (GINA). The severity of airway obstruction varied between the trials, with the participants with the lowest percentage predicted of FEV1 recruited to SAM40048 (65%), Busse 2008; EXCEL and COMPASS recruiting participants with moderate airway obstruction (79%, 79% and 73% respectively), and participants with milder obstruction represented in Aalbers 2004 (84%).
Interventions & comparisons
Converting the inhaled steroid load to BDP equivalent indicated that the trials assessed high doses of inhaled steroids in both FP/ SAL and BUD/F groups, although FP/SAL was higher in BDP equivalence terms than BUD/F (1000 versus 400-800 mcg/day). All doses were given twice daily via different inhalers (Diskus and Turbohaler for FP/SAL and BUD/F respectively). Two studies were open label (Aalbers 2004; Busse 2008) . In all studies the dose of FP/SAL was 500/100 mcg/day, and that of BUD/F was 400-800/12-24 mcg/day. Concomitant use of reliever medication was permitted in all four studies; terbutaline in COMPASS, salbutamol in Busse 2008 and EXCEL, and terbutaline or salbutamol as preferred in Aalbers 2004. In SAM40048 the reliever medication was not reported.
Outcomes
Four trials measured exacerbations as oral steroid and hospitalisations (Aalbers 2004; Busse 2008; EXCEL; COMPASS), and also gave numerical data for serious adverse events. All studies reported lung function measurements. Data on admission to hospital were made available to the review authors on request from GSK and AZ for Aalbers 2004; COMPASS; EXCEL. We were informed verbally that exacerbations were not collected in a way that was suitable for us to use in our review in SAM40048.
Excluded studies
A total of 19 studies failed to meet the review eligibility criteria. The reasons for their exclusion are listed in Characteristics of excluded studies.
Risk of bias in included studies
See Figure 2 and Figure 3 for summaries of risk of bias. Additional details on items are provided in Characteristics of included studies. Generally the studies were well designed although reliable assessment of selective reporting could not be ascertained. Primary outcome data were either reported in the studies or made available to the authors on request. 
Allocation
The four studies available as full-text articles reported computergenerated randomisation sequences, with adequate concealment of treatment group allocation. Demographic characteristics of all four of the studies indicated that treatment groups were well balanced. Details on SAM40048 were not adequately reported for us to establish the appropriateness of the concealment of allocation.
Blinding
We used outcome data from an open label phase in two studies (Aalbers 2004; Busse 2008) . The remaining studies used a doubledummy design to control for awareness of treatment group allocation. Blinding of outcome assessment was not reported in the studies.
Incomplete outcome data
Intention to treat analyses were used in all of the studies based on the population randomised, but explicit description of follow-up and handling of missing data were not provided.
Selective reporting
We needed to contact the study sponsors of Aalbers 2004; COMPASS for data pertaining to our primary outcomes of exacerbations (AstraZeneca). The sponsors of EXCEL confirmed data on the primary outcomes, and made available data for exacerbations leading to ED visits and admission to hospital (see Published notes).
Effects of interventions
See: Summary of findings for the main comparison Combination fluticasone/salmeterol or budesonide/formoterol for chronic asthma in adults Using published data and unpublished data obtained through correspondence with manufacturers, we included four of the five eligible trials in the three co-primary outcomes representing 88% of randomised participants.
FP/SAL 500/100 mcg/d versus BUD/F 400-800/12-24 mcg/d
The comparisons are presented such that a reduction in the mean difference greater than 0, or an odds ratio of less than one represent a lowering for the FP/SAL group compared to the BUD/F group (the associated confidence intervals and P value indicate the statistical significance of this). In view of the absence of studies in children, the evidence we have relates to adults.
Primary outcomes
Exacerbations & asthma related serious adverse events The Summary of Findings table conveys the results of these outcomes as absolute effects and our assessment of the strength of the evidence (Summary of findings for the main comparison).
Secondary outcomes
Exacerbations requiring ED visit/hospital admission (composite)
There was no statistically significant difference in the odds of ED visit/admission to hospital between the treatments (four studies, OR 1.3; 95% CI 0.94 to 1.8, N = 4861, Analysis 1.4).
Diary card peak flow
There was no significant difference between treatments in mean change in morning (five studies, 2.24 L/min, 95% CI -0.24 to 4.73, N = 5101) or evening peak flow (four studies, 0.25 L/min; 95% CI -0.80 to 1.30, N = 4299).
FEV1
There was no significant difference in the change from baseline between treatments (three studies, 0 Litres; 95% CI -0.02 to 0.02, N = 4845).
Symptoms & rescue medication use
There was no significant difference between treatments in the mean change in symptom scores (three studies, -0.02; 95% CI -0.6 to 0.03, N = 3464). There was also no significant difference in change in rescue medication (three studies -0.06 puffs per day; 95% CI -0.13 to 0.02, N = 3469).
Withdrawals and tolerability
Study withdrawals were not significantly more frequent with either treatment in terms of overall discontinuations (Analysis 1.13), or when withdrawal due to adverse events or lack of efficacy were considered Analysis 1.14; Analysis 1.15. Headache, upper respiratory tract infection, dysphonia and throat irritation did not differ significantly between treatments (Analysis 1.17; Analysis 1.20; Analysis 1.19; Analysis 1.22). A summary of findings table has been incorporated to this version of the review. This outlines our assessment of the overall quality of the evidence based on the risk of bias assessments, availability of data, imprecision of our analyses, and size and direction of the results (Summary of findings for the main comparison). In view of the absence of studies in children, the findings of the review are directly relevant to adults with asthma.
D I S C U S S I O N
This review has collected data from five well-designed studies randomising over 5000 patients. No studies recruited children under the age of 12 years. The dose comparisons across the studies were similar, except for SAM40048 where the dose of budesonide was half of that in the other studies. Based on UK recommendations, the BUD/F dose was the maximum licensed dosing for asthma in the UK, and the FP/SAL dose is the medium dose recommended in the UK for asthma (BNF 2007) . We identified three co-primary outcomes, two pertaining to different severities of asthma exacerbation (those requiring oral steroid treatment, and those leading to hospitalisation), and one relating to asthma-related serious adverse events. None of the results were statistically significant. Our assessment of the quality of the evidence for these outcomes was moderate. Findings from these three endpoints will be considered first.
Requirement for a course of oral steroid treatment is a treatmentdriven rather than symptom-driven definition, but gives some in-dication as to whether maintenance therapy reduces inflammation sufficiently to prevent requirement for additional steroid. The ratio of such events was close to 1 in the three studies, and the BUD/ F event rate was similar between the trials (Aalbers 2004: 15%; Busse 2008: 9%; EXCEL: 11%; COMPASS: 10%). The lack of a statistically significant difference may reflect the effectiveness of combination therapy in reducing exacerbations when added to monotherapy ICS (Greenstone 2005).
The risk of hospitalisation did not differ significantly between therapies, although the confidence interval was wide and further evidence is necessary before a conclusion of no difference could be drawn definitively. The morbidity associated with hospital admission is considerable, and may indicate severe uncontrolled disease as well as predict future hospitalisation and mortality (Suissa 2001). Superiority of FP over BUD in dose ratio comparisons of 1: 1 and 1:2 has been demonstrated for lung function endpoints, but not exacerbation rate data (Adams 2007). Our composite analysis of ED visit/hospitalisation did not show a significant difference between the treatments in contrast to a previous meta-analysis (Edwards 2007). The data for that analysis were in part based upon hospitalisation data from EXCEL and not additional ED visits from that study. Given that the data we obtained from GSK suggested parity between these event rates, we consider our data to represent a more complete assessment of the evidence available.
Based on evidence of harm, the use of LABAs as monotherapy is not recommended with serious adverse event data from previous studies implicating the bronchodilatory effects of LABAs as a possible mask for under-treated deterioration in underlying airway inflammation (Walters 2007; Cates 2008a; Cates 2008b) . Serious adverse events did not occur with sufficient frequency in the studies to give precision to the results of our meta-analysis. The relative effects of either treatment in terms of serious harms remain to be fully elucidated. Based on evidence drawn from other comparisons involving adding LABA to ICS preparations, these therapies are well-tolerated (Greenstone 2005; Ni Chroinin 2005) .
Neither lung function parameters, symptom scores nor rescue medication use identified statistically significant differences between treatments. Adverse event data indicated that the drugs were equally well-tolerated.
There are several limitations of the review. We limited our analyses to parallel studies on the assumption that optimum washout in steroid trials is uncertain, and that our primary outcome of exacerbations was best measured in long-term studies with a betweenpatient design. We have assumed that requirement for oral steroids and admission to hospital are independent, although it is reasonable to expect that poor asthma control associated with lack of adherence to maintenance inhaled steroids is likely to predict both (Williams 2004). Assessment of patient severity was confined to GINA defined control status, and this may not be sensitive enough to discern between severities of asthma. The major limitation of the studies themselves is the absence of data in children under the age of 12 years.
A U T H O R S ' C O N C L U S I O N S Implications for practice
The confidence intervals for our estimates in our primary outcomes include no statistically significant difference. However, the width of the confidence intervals for these endpoints also include possibly meaningful differences between the treatments in either direction and as such more evidence would help to improve their precision. Serious adverse events were too infrequent to generate findings which could be easily interpreted. Our analyses could not detect significant differences between these drugs in terms of lung function and symptoms. These observations pertain to adults and adolescents whose asthma is not adequately controlled with high doses of inhaled steroids.
Implications for research
The findings of our review would be strengthened by more data on exacerbations from further trials, in particular trials that include visits to emergency departments and hospitalisation. Evidence is required to establish the ratio of serious adverse events between these two drugs. Evidence for the effects of these drugs in children is also required.
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N O T E S
A previous version of this review was withdrawn prior to publication following the identification of incomplete data by GSK for the outcome ED visit/admission to hospital. The data included in the original version of the review indicated a significant increase in the odds of ED visit/hospitalisation with FP/SAL. However, this reflected data that were drawn from those participants who were admitted to hospital only. The pooled outcome data did not an accurately represent the composite outcome of presentation at ED or hospital admission (EXCEL). We have now included data made available to us by GSK which are an accurate record of ED visit or admission to hospital.
